Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. retindr

RetinDR SIGNED

RetinDR: The first topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RetinDR project word cloud

Explore the words cloud of the RetinDR project. It provides you a very rough idea of what is the project "RetinDR" about.

agreements    usually    neurodegeneration    treatment    share    peripheral    difficulty    europeans    estimate    115    successful    jobs    sales    arterial    symptoms    industrial    eye    treats    reading    endothelin    receptor    formulation    93    suffer    3    model    business    ophthalmic    pharmaceutical    drug    2025    floaters    royalties    wacc    forecast    5    final    till    indicated    revenues    blurred    retinal    stages    million    sme    15    prevention    completion    2016    1    repurposing    diabetic    receive    seeing    feasibility    pulmonary    retinopathy    21m    commercialization    cagr    plan    topical    vision    licensing    spots    double    limited    market    progresses    prevents    months    grow    drops    52m    outside    worldwide    98    retindr    hypertension    antagonist    npv    people    aggressive    treatments    aged    accounted    markets    substance    81b    blindness    effectiveness    aging    strategic    bosentan    dr    parent    considering    ebitda    equalling    irr    quite    22    disease    global    medical    adults    co    commercialisation    mix    55m    diabetes    company   

Project "RetinDR" data sheet

The following table provides information about the project.

Coordinator		 RETINSET SL 

Organization address
address: AMPOSTA 20
city: SANT CUGAT DEL VALLES
postcode: 8174
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RETINSET SL ES (SANT CUGAT DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR.

The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties.

With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETINDR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETINDR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More